Opinion|Videos|October 4, 2024
NCCN Guideline Updates in Clear-Cell RCC
Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
NCCN guidelines have been updated to reflect ipilimumab + plus nivolumab as a preferred regimen in patients with favorable risk. What data supported this change, and how do you see it affecting the disease landscape?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5